VIPR2 anticorps (AA 334-393)
Aperçu rapide pour VIPR2 anticorps (AA 334-393) (ABIN1886376)
Antigène
Voir toutes VIPR2 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 334-393
-
Purification
- Purified by antigen-affinity chromatography.
-
Immunogène
- Synthetic peptide contain a sequence corresponding to a region within amino acids 334 and 393 of Human VIPR2
-
-
-
-
Indications d'application
-
Suggested dilutions:
Western blotting: 1.500-1.3000 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- 0.1 M Tris-buffered saline with 10 % Glycerol (pH 7.0).0.01 % Thimerosal was added as a preservative.
-
Agent conservateur
- Thimerosal (Merthiolate)
-
Précaution d'utilisation
- Biohazard Informations: This product contains thimerosal which is hazardous.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.
-
-
- VIPR2 (Vasoactive Intestinal Peptide Receptor 2 (VIPR2))
-
Autre désignation
- VPAC2
-
Sujet
-
Vasoactive intestinal peptide (VIP, MIM 192320) and pituitary adenylate cyclase activating polypeptide (PACAP, MIM 102980) are homologous peptides that function as neurotransmitters and neuroendocrine hormones.While the receptors for VIP and PACAP share homology, they differ in their substrate specificities and expression patterns.See VIPR1 (MIM 192321) and ADCYAP1R1(MIM 102981).[supplied by OMIM]
-
Poids moléculaire
- 49 kDa
-
ID gène
- 7434
-
NCBI Accession
- NP_003373, NM_003382
-
Pathways
- cAMP Metabolic Process
Antigène
-